Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
about
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaHealthcare-associated infections, infection control and the potential of new antibiotics in development in the USAClinical management of infections caused by multidrug-resistant EnterobacteriaceaeNew β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Ceftaroline fosamil: a brief clinical review.Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Investigational antimicrobial agents of 2013.Interaction of Avibactam with Class B Metallo-β-Lactamases.Pipeline of Known Chemical Classes of Antibiotics.β-Lactam Antibiotics Renaissance.Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance studySpa Typing of Staphylococcus aureus Strains Isolated From Clinical Specimens of Patients With Nosocomial Infections in Tehran, Iran.Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistanceCeftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic modelβ-Lactam antimicrobials: what have you done for me lately?New β-lactam-β-lactamase inhibitor combinations in clinical development.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam.β-Lactams and β-Lactamase Inhibitors: An Overview.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groupsPharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.Bioanalytical method validation for the simultaneous determination of ceftazidime and avibactam in rat plasma.Avibactam Pharmacokinetic/Pharmacodynamic Targets.β-lactam/β-lactamase inhibitor combinations: an update
P2860
Q24601746-56B6A7AD-8EE2-4485-BEED-A7905BA71B64Q26995305-8C4CB23A-B762-43FA-B2AC-F5C039DAB61AQ28246841-841960CD-7E80-4CEC-BB2B-7F3D56F24999Q33622976-695B85BE-EE55-4806-A163-520EE9126951Q33939080-E49AC089-1644-4900-B70C-6DAFFB51F4AEQ34058217-2B33678D-6FCE-4875-8CE2-3F3D59878844Q34375204-3AC9106A-F6B9-468E-A9D4-61CEBE5F5D05Q34533834-58A8F154-4A45-4294-AEE9-AF6C8BE84E40Q36683409-589C4A50-647C-41FB-8623-F3965BD90E99Q36683689-58D48E6D-3E55-4474-8D8C-5AEDE62056A3Q37146405-103DCF5F-A3F8-492A-8167-004BE520E8FDQ37263425-476129DF-6A78-441E-AAB1-71152DAEBF04Q37280568-C5F38FA0-6E3D-4AE7-B4B3-34DFB6C8689BQ37411475-06DB26F2-ADBF-4879-B1B3-BD9EB1DE04A5Q37544518-C33EF2F2-4D12-40DB-B32E-82C781142A91Q38076453-950857B1-5EEA-4FF0-A999-D88748069B22Q38076455-9F28D044-85A9-4941-A7EE-81285B60C91DQ38117077-6338E582-91DC-4A41-8234-BB28CDB055A5Q38130715-EE4D5064-58DB-4D56-AA3D-53505F2D6848Q38850240-F479D8F7-FE22-40CB-A824-FD10A3708175Q38872374-F53E110D-C12C-48C5-A30D-45C19761D89CQ38892589-97C01CCB-C9EE-457B-89C7-EA072A07265DQ39120027-A281B64B-85EC-4CF8-845D-FC339A03D73BQ39766920-9DAD2F49-077E-42FB-A391-8E8274EC907FQ41379541-29B92486-058F-41C4-9AFA-D4D65C08471FQ41907738-43AB57F5-31D4-4E9B-B77F-E6C685B0AB72Q43085417-22D6BD24-2825-4C24-8A2F-78BE5C5B39BCQ50903796-726D3254-F90A-45F0-A130-252062F5E2F7Q52611981-AF359F37-40E0-42FA-A297-89E0BDBB223AQ57133147-F4DA911A-044D-4931-819C-8931F6046C71
P2860
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Activity of ceftaroline-avibac ...... cassette chromosome mec types.
@en
type
label
Activity of ceftaroline-avibac ...... cassette chromosome mec types.
@en
prefLabel
Activity of ceftaroline-avibac ...... cassette chromosome mec types.
@en
P2093
P2860
P921
P356
P1476
Activity of ceftaroline-avibac ...... cassette chromosome mec types.
@en
P2093
David J Farrell
Rodrigo E Mendes
Ronald N Jones
P2860
P304
P356
10.1128/AAC.00817-12
P407
P577
2012-06-25T00:00:00Z